TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 41, 2018, Pages 10440-10445

  Bottermann, Maria ^a   Foss, Stian ^b,c   Van Tienen, Laurens M ^a   Vaysburd, Marina ^a   Cruickshank, James ^a   O'Connell, Kevin ^a   Clark, Jessica ^a   Mayes, Keith ^a   Higginson, Katie ^a   Hirst, Jack C ^d   McAdam, Martin B ^c   Slodkowicz, Greg ^a   Hutchinson, Edward ^d   Kozik, Patrycja ^a   Andersen, Jan Terje ^b,c   James, Leo C ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adenovirus; Gene therapy; Host pathogen; TRIM21; Viral vector

Indexed keywords

ANTIBODY; RIBONUCLEOPROTEIN; SS-A ANTIGEN;

ADENOVIRIDAE; ADENOVIRUS INFECTION; ANIMAL; C57BL MOUSE; FIBROSARCOMA; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MOUSE; PHYSIOLOGY; TRANSGENE; TUMOR CELL CULTURE; VACCINATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIBODIES; FIBROSARCOMA; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RIBONUCLEOPROTEINS; TRANSGENES; TUMOR CELLS, CULTURED; VACCINATION;

EID: 85054758783     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1806314115     Document Type: Article

References (42)

1. The Journal of Gene Medicine (2017) Vectors used in gene therapy clinical trials, updated November 2017. Available at abedia.com/wiley/vectors.php. Accessed November 15, 2017.
2. Crystal RG (2014) Adenovirus: The first effective in vivo gene delivery vector. Hum Gene Ther 25:3-11.
3. Abbink P, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
4. Nwanegbo E, et al. (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, the United States. Clin Diagn Lab Immunol 11:351-357.
5. Sumida SM, et al. (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185.
6. Varnavski AN, et al. (2002) Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol 76:5711-5719.
7. McCoy K, et al. (2007) Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol 81:6594-6604.
8. Pine SO, et al. (2011) Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 6: E18526.
9. Sumida SM, et al. (2004) Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78: 2666-2673.
10. Youil R, et al. (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13:311-320.
11. Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH (2012) Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 86:625-629.
12. Bradley RR, et al. (2012) Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86:1267-1272.
13. Luisoni S, et al. (2015) Co-option of membrane wounding enables virus penetration into cells. Cell Host Microbe 18:75-85.
14. Burckhardt CJ, et al. (2011) Drifting motions of the adenovirus receptor CAR and immobile integrins initiate virus uncoating and membrane lytic protein exposure. Cell Host Microbe 10:105-117.
15. Mallery DL, et al. (2010) Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA 107:19985-19990.
16. Fletcher AJ, Mallery DL, Watkinson RE, Dickson CF, James LC (2015) Sequential ubiquitination and deubiquitination enzymes synchronise the dual sensor and effector functions of TRIM21. Proc Natl Acad Sci USA 112:10014-10019.
17. Fletcher AJ, James LC (2016) Coordinated neutralization and immune activation by the cytosolic antibody receptor TRIM21. J Virol 90:4856-4859.
18. McEwan WA, et al. (2013) Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14:327-336.
19. Watkinson RE, McEwan WA, Tam JCH, Vaysburd M, James LC (2015) TRIM21 promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus. PLoS Pathog 11:e1005253.
20. Bottermann M, et al. (2016) Antibody-antigen kinetics constrain intracellular humoral immunity. Sci Rep 6:37457.
21. Xu Z, Tian J, Smith JS, Byrnes AP (2008) Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, complement. J Virol 82: 11705-11713.
22. Wines BD, Powell MS, Parren PWHI, Barnes N, Hogarth PM (2000) The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol 164:5313-5318.
23. Vaysburd M, et al. (2013) Intracellular antibody receptor TRIM21 prevents fatal viral infection. Proc Natl Acad Sci USA 110:12397-12401.
24. Foss S, et al. (2016) TRIM21 immune signaling is more sensitive to antibody affinity than its neutralization activity. J Immunol 196:3452-3459.
25. Kim JK, et al. (1999) Mapping the site on human IgG for binding of the MHC class Irelated receptor, FcRn. Eur J Immunol 29:2819-2825.
26. Snijder J, et al. (2013) Integrin and defensin modulate the mechanical properties of adenovirus. J Virol 87:2756-2766.
27. Stone D, et al. (2007) Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol 81:4866-4871.
28. Tao N, et al. (2001) Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3:28-35.
29. Richardson JS, Pillet S, Bello AJ, Kobinger GP (2013) Airway delivery of an adenovirusbased Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 87:3668-3677.
30. Zeelenberg IS, et al. (2008) Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 68:1228-1235.
31. Sedlik C, et al. (2014) Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicleassociated forms. J Extracell Vesicles 3:24646.
32. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM (2005) Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther 12:427-436.
33. Zak DE, et al. (2012) Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 109:E3503-E3512.
34. Higgs R, et al. (2008) The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 181:1780-1786.
35. Higgs R, et al. (2010) Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One 5:e11776.
36. Zhang Z, et al. (2013) The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol 14:172-178.
37. Kafri T, et al. (1998) Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc Natl Acad Sci USA 95:11377-11382.
38. Muruve DA, Barnes MJ, Stillman IE, Libermann TA (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10:965-976.
39. Vlachaki MT, et al. (2002) Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 6:342-348.
40. Dhar D, Spencer JF, Toth K, Wold WS (2009) Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 17:1724-1732.
41. Crystal RG, et al. (2002) Analysis of risk factors for local delivery of low-A nd intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther 13:65-100.
42. Wilson JM (2009) Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96:151-157.